Kyverna Completes Miv-cel BLA Submission in SPS

Kyverna disclosed November 12 that it completed its rolling FDA biologics license application for mivocabtagene autoleucel in stiff person syndrome (SPS) and requested priority review. Completion is a regulatory submission event; FDA acceptance, review…













